Nottingham, United Kingdom
Nottingham, United Kingdom
SEARCH FILTERS
Time filter
Source Type

News Article | July 11, 2017
Site: www.prnewswire.com

This report provides an overview of the skeletal disease pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for osteoporosis, post-menopausal osteoporosis and osteoarthritis (OA). OA is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. There are a total of 116 products in development for this indication, by 87 companies and 8 academic institutions. Key companies operating in this pipeline space include Arcarios, Nordic Bioscience, Rottapharm Biotech and the University of Toledo. Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. There are a total of 112 products in development for this indication, by 80 companies and 16 academic institutions. Key companies operating in this pipeline space include Max Biopharma, Omeros, Affilogic laboratories, Amgen and the University of Wisconsin Madison. Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. There are a total of 13 products in development for this indication, by ten companies. Key companies operating in this pipeline space include Amgen and Ipsen. The predominant targets within OA are prostaglandin G/H synthases 1 and 2, although a wide range of targets, including extracellular matrix-organizing proteins and interleukins, are being studied. Likewise, within both osteoporosis and the post-menopausal subtype, a broad range of molecular targets are being studied. The targets being most frequently studied are the parathyroid hormone receptor, tumor necrosis factor ligand superfamily member 11 and sclerostin. Scope - Which companies are the most active within the pipeline for osteoporosis and OA therapeutics? - Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication? - To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? - What are the most important R&D milestones and data publications to have happened in the field of osteoporosis and OA therapeutics? Key Topics Covered: 1. Research Report Guidance 2. Executive Summary 3. Introduction 4. Skeletal Disease Report Coverage 5. Therapeutics Development 6. Therapeutics Assessment 7. Companies Involved in Therapeutics Development 8. Dormant Projects 9. Discontinued Products 10. Product Development Milestones 11. Appendix - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc - Abiogen Pharma SpA - Ablynx NV - Achelios Therapeutics Inc - Addex Therapeutics Ltd - Alize Pharma SAS - Alvogen Korea Co Ltd - Amgen Inc - Amura Holdings Ltd - Arcarios BV - Asahi Kasei Pharma Corp - Asklepios BioPharmaceutical Inc - Astellas Pharma Inc - BiologicsMD Inc - Biopharm GmbH - Bone Biologics Corp - Bone Therapeutics SA - Bristol-Myers Squibb Company - Can-Fite BioPharma Ltd - Cardax Inc - Cellmid Ltd - Cellular Biomedicine Group Inc - ChoDang Pharm Co Ltd - Chugai Pharmaceutical Co Ltd - Cipla Ltd - Corestem Inc - Corium International Inc - Critical Pharmaceuticals Ltd - Daiichi Sankyo Company Ltd - Dong-A Socio Holdings Co Ltd - ElexoPharm GmbH - EndoCeutics Inc - Entera Bio Ltd - Enteris BioPharma Inc - Enzo Biochem Inc - Evgen Pharma Plc - F. Hoffmann-La Roche Ltd - GL Pharm Tech Corp - Gador SA - Galapagos NV - Gemphire Therapeutics Inc - GeneFrontier Corp - Genequine Biotherapeutics GmbH - GlaxoSmithKline Plc - Glide Pharmaceutical Technologies Ltd - HSRx Group - Hanmi Pharmaceuticals Co Ltd - Haoma Medica Ltd - Immunovo BV - Immunwork Inc - InKemia IUCT Group SA - Intas Pharmaceuticals Ltd - International Stem Cell Corp - Ipsen SA - Jeil Pharmaceutical Co Ltd - Jenrin Discovery Inc - K-Stemcell Co Ltd - Kaken Pharmaceutical Co Ltd - Kang Stem Biotech Co Ltd - LG Chem, Ltd. - Lead Discovery Center GmbH - Levolta Pharmaceuticals Inc - Ligand Pharmaceuticals Inc - Lotus Pharmaceutical Co Ltd - Lupin Ltd - Marina Biotech Inc - Medivir AB - Merck & Co Inc - Merck KGaA - Mereo Biopharma Group Plc - Mesoblast Ltd - Mor Research Application Ltd - NIBEC - NicOx SA - Nordic Bioscience A/S - Novartis AG - NovelMed Therapeutics Inc - Omeros Corp - Oncobiologics Inc - Ono Pharmaceutical Co Ltd - OrthoCyte Corp - Osteologix Holdings Plc - PLx Pharma Inc - Paras Biopharmaceuticals Finland Oy - Pfenex Inc - Pfizer Inc - Pharmalink AB - Philogen SpA - PhytoHealth Corp - ProteoThera Inc - R Pharm - Regeneus Ltd - Regulaxis SAS - Ribomic Inc - Rottapharm Biotech Srl - Samumed LLC - Seikagaku Corp - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd - Shin Poong PharmCo Ltd - Sinil Pharmaceutical Co Ltd - Stelis Biopharma Pvt Ltd - Sumitomo Dainippon Pharma Co Ltd - TSH Biopharm Corporation Ltd - Takeda Pharmaceutical Company Ltd - Terpenoid Therapeutics Inc - TissueGene Inc - Uni-Bio Science Group Ltd - Viking Therapeutics Inc - Wroclawskie Centrum Badan EIT+ Sp z oo - Yooyoung Pharm Co Ltd - Yooyoung Pharmaceutical Co Ltd - Yuhan Corp - Yungjin Pharm Co Ltd - Zimmer Biomet Holdings Inc - Zydus Cadila Healthcare Ltd For more information about this report visit https://www.researchandmarkets.com/research/jdvvhm/skeletal_disease Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716


The report "Schizophrenia - Pipeline Review, H1 2017" provides comprehensive information on the therapeutics under development for Schizophrenia (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Complete report on Schizophrenia - Pipeline Review, H1 2017 spread across 309 pages is available at http://www.rnrmarketresearch.com/schizophrenia-pipeline-review-h1-2017-market-report.html . Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 12, 13, 22, 1, 54, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 9 and 2 molecules, respectively. Companies discussed in this report include Acadia Pharmaceuticals Inc, Adamed Sp z oo, Aequus Pharmaceuticals Inc, AgeneBio Inc, Alkermes Plc, Angita BV, Astellas Pharma Inc, Athersys Inc, Avanir Pharmaceuticals Inc, Avineuro Pharmaceuticals Inc, BCWorld Pharm Co Ltd, BioCrea GmbH, BioHealthonomics Inc, Boehringer Ingelheim GmbH, Braeburn Pharmaceuticals Inc, Bristol-Myers Squibb Company, Critical Pharmaceuticals Ltd, Curemark LLC, Daewoong Pharmaceutical Co Ltd, Delpor Inc, Denovo Biopharma LLC, Evotec AG, F. Hoffmann-La Roche Ltd, Fabre-Kramer Pharmaceuticals Inc, Galenea Corp, GeNeuro SA, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, GP Pharm SA, GW Pharmaceuticals Plc, H. Lundbeck A/S, Heptares Therapeutics Ltd, Hisamitsu Pharmaceutical Co Inc, Indivior Plc, Insys Therapeutics Inc, IntelGenx Corp, Intra-Cellular Therapies Inc, Johnson & Johnson, JT Pharmaceuticals Inc, Karuna Pharmaceuticals Inc, KemPharm Inc, Kowa Company Ltd, Laboratorios Farmaceuticos Rovi SA, Lead Discovery Center GmbH, Lohocla Research Corp, Luye Pharma Group Ltd, Mapi Pharma Ltd, Merck & Co Inc, Mitsubishi Tanabe Pharma Corp, Neurocrine Biosciences Inc, NeurOp Inc, Newron Pharmaceuticals SpA, Omeros Corp, Otsuka Holdings Co Ltd, Peptron Inc, Pfizer Inc, Promentis Pharmaceuticals Inc, Ra Pharmaceuticals Inc, Reviva Pharmaceuticals Inc, Richter Gedeon Nyrt, Sage Therapeutics Inc, SK Biopharmaceuticals Co Ltd, Sumitomo Dainippon Pharma Co Ltd, Sunovion Pharmaceuticals Inc, Suven Life Sciences Ltd, Taisho Pharmaceutical Holdings Co Ltd, Tetra Discovery Partners LLC, Teva Pharmaceutical Industries Ltd, Vanda Pharmaceuticals Inc, Vitality Biopharma Inc, VLP Therapeutics LLC, Zogenix Inc, Zysis Ltd Order a copy of this research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=1019645. (This report is available at up to 25% Discount till June 02nd 2017.) "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2017", provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Explore more reports of Therapeutics Market Research at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics . RnRMarketResearch.com is your one stop market research and industry analysis reports' library providing business data and intelligence information on thousands of micro markets with global as well as regional coverage. Category focused research, country reports, company profiles, regional and global industry profiles and guides to premium reports offering extensive coverage of other 20+ industries are all available in our library of syndicated market research reports.


The report "Schizophrenia - Pipeline Review, H1 2017" provides comprehensive information on the therapeutics under development for Schizophrenia (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Complete report on Schizophrenia - Pipeline Review, H1 2017 spread across 309 pages is available at http://www.rnrmarketresearch.com/schizophrenia-pipeline-review-h1-2017-market-report.html . Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 12, 13, 22, 1, 54, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 9 and 2 molecules, respectively. Companies discussed in this report include Acadia Pharmaceuticals Inc, Adamed Sp z oo, Aequus Pharmaceuticals Inc, AgeneBio Inc, Alkermes Plc, Angita BV, Astellas Pharma Inc, Athersys Inc, Avanir Pharmaceuticals Inc, Avineuro Pharmaceuticals Inc, BCWorld Pharm Co Ltd, BioCrea GmbH, BioHealthonomics Inc, Boehringer Ingelheim GmbH, Braeburn Pharmaceuticals Inc, Bristol-Myers Squibb Company, Critical Pharmaceuticals Ltd, Curemark LLC, Daewoong Pharmaceutical Co Ltd, Delpor Inc, Denovo Biopharma LLC, Evotec AG, F. Hoffmann-La Roche Ltd, Fabre-Kramer Pharmaceuticals Inc, Galenea Corp, GeNeuro SA, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, GP Pharm SA, GW Pharmaceuticals Plc, H. Lundbeck A/S, Heptares Therapeutics Ltd, Hisamitsu Pharmaceutical Co Inc, Indivior Plc, Insys Therapeutics Inc, IntelGenx Corp, Intra-Cellular Therapies Inc, Johnson & Johnson, JT Pharmaceuticals Inc, Karuna Pharmaceuticals Inc, KemPharm Inc, Kowa Company Ltd, Laboratorios Farmaceuticos Rovi SA, Lead Discovery Center GmbH, Lohocla Research Corp, Luye Pharma Group Ltd, Mapi Pharma Ltd, Merck & Co Inc, Mitsubishi Tanabe Pharma Corp, Neurocrine Biosciences Inc, NeurOp Inc, Newron Pharmaceuticals SpA, Omeros Corp, Otsuka Holdings Co Ltd, Peptron Inc, Pfizer Inc, Promentis Pharmaceuticals Inc, Ra Pharmaceuticals Inc, Reviva Pharmaceuticals Inc, Richter Gedeon Nyrt, Sage Therapeutics Inc, SK Biopharmaceuticals Co Ltd, Sumitomo Dainippon Pharma Co Ltd, Sunovion Pharmaceuticals Inc, Suven Life Sciences Ltd, Taisho Pharmaceutical Holdings Co Ltd, Tetra Discovery Partners LLC, Teva Pharmaceutical Industries Ltd, Vanda Pharmaceuticals Inc, Vitality Biopharma Inc, VLP Therapeutics LLC, Zogenix Inc, Zysis Ltd Order a copy of this research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=1019645. (This report is available at up to 25% Discount till June 02nd 2017.) "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2017", provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Explore more reports of Therapeutics Market Research at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics . RnRMarketResearch.com is your one stop market research and industry analysis reports' library providing business data and intelligence information on thousands of micro markets with global as well as regional coverage. Category focused research, country reports, company profiles, regional and global industry profiles and guides to premium reports offering extensive coverage of other 20+ industries are all available in our library of syndicated market research reports.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 139.92K | Year: 2015

Age-related macular degeneration (AMD) is the leading cause of blindness in those aged over 50, causing blurring, distortion and loss of central vision and almost always affects quality of life. There are two main types of AMD, wet and dry. Wet AMD is most severe but more treatable and occurs in about 1 in 10 cases. However it causes severe visual loss over a short time, sometimes just months or even hours / days if there is a haemorrhage. Current treatment requires monthly injections into the eye, which are unpleasant for the patient and carry a risk of infection. This project aims to prepare a novel, sustained release treatment to reduce the necessary frequency of injections, improving the patient experience and reducing the risks and costs of treatment.


Patent
Critical Pharmaceuticals | Date: 2016-04-27

A process for preparing microparticles comprising a biologically active material and a polymer and having a mean particle size expressed as the volume mean diameter (VMD) of from 10 to 500 m, wherein the biologically active material is substantially insoluble in the polymer, which process comprises:a. contacting a mixture of the biologically active material or a precursor thereof , the polymer or a precursor thereof and a processing aid with a supercritical fluid which is capable of swelling the polymer under temperature and pressure conditions necessary to maintain the fluid in a supercritical state;b. allowing the supercritical fluid to penetrate and liquefy the polymer, whilst maintaining the temperature and pressure conditions so that the fluid is maintained in a supercritical state;c. releasing the pressure to precipitate microparticles comprising the biologically active agent and the polymer.


There is provided a supercritical fluid-based process for preparing a solid polymer matrix containing a core material, wherein the process includes the step of mixing the polymer, core material and supercritical fluid in a mixing vessel, followed at least one cycle of, without recovering the solid polymer matrix, (i) converting the supercritical fluid in the mixing vessel to a sub-critical state, and then (ii) returning the fluid to the supercritical state, provided that the core material does not comprise any of gonadotropin releasing hormone (GnRH), a GnRH agonist and a GnRH antagonist.


Patent
Critical Pharmaceuticals | Date: 2013-11-14

Absorption of a therapeutic agent across a mucosal membrane or the skin can be enhanced using an absorption enhancer comprising a hydroxy fatty acid ester of polyethylene glycol.


Patent
Critical Pharmaceuticals | Date: 2015-11-20

A process for preparing microparticles comprising a biologically active material and a polymer and having a mean particle size expressed as the volume mean diameter (VMD) of from 10 to 500 m, wherein the biologically active material is substantially insoluble in the polymer, which process comprises: a. contacting a mixture of the biologically active material or a precursor thereof, the polymer or a precursor thereof and a processing aid with a supercritical fluid which is capable of swelling the polymer under temperature and pressure conditions necessary to maintain the fluid in a supercritical state; b. allowing the supercritical fluid to penetrate and liquefy the polymer, whilst maintaining the temperature and pressure conditions so that the fluid is maintained in a supercritical state; c. releasing the pressure to precipitate microparticles comprising the biologically active agent and the polymer.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 177.86K | Year: 2012

We plan to develop a nasal spray formulation of PTH1-34 for the treatment of osteoporosis using the CriticalSorb absorption enhancer. Osteoporosis is a prevalent disease (effecting 40% of women by age 80), characterised by reduced bone density and increased risk of fracture, particularly of the hip, wrist and spine, at a cost to the NHS of >£2bn per annum. PTH1-34 is the only drug available that stimulates the formation of new bone, but currently needs to be injected every day. Not only is this invasive method of drug administration not well liked by patients, but it is a complicated multi-step process and as osteoporosis patients are elderly they can find it difficult. The nasal spray we develop is expected to improve ease of use, increase patient compliance with the treatment regimen and increase efficacy with the aim of improving treatments and reducing healthcare costs.


Grant
Agency: European Commission | Branch: H2020 | Program: SME-1 | Phase: NMP-25-2014-1 | Award Amount: 71.43K | Year: 2015

Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration This feasibility study is to verify the technical and economic viability of a sustained release bevacizumab product (SR Bevacizumab) to improve the safety, cost-effectiveness and patient acceptability for the treatment of wet age-related macular degeneration (AMD). AMD is the leading cause of blindness in those aged over 50 and causes blurring, distortion and loss of central vision and almost always affects quality of life. Prototype SR Bevacizumab products will be manufactured using CriticalMix, an advanced manufacturing and processing technology developed by Critical Pharmaceuticals, which will encapsulate bevacizumab in biodegradable polymers suitable for sustained release of the drug in the eye.

Loading Critical Pharmaceuticals collaborators
Loading Critical Pharmaceuticals collaborators